Experts, Expertise and Drug Policymaking
Experts, Expertise and Drug Policymaking
复制标题
专家、专业知识和药物政策制定
DOI：
--
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Kate Wicker
中科院分区：
文献类型：
--
作者：
Mark Monaghan;E. Wincup;Kate Wicker
在过去的二十年里，政策制定者一直被鼓励与专家合作制定基于证据的政策。药物政策是独特的，因为它有一个既定的内在机制，通过滥用药物问题咨询理事会征求专门知识。越来越多地使用替代机制。基于两个案例研究的药物政策制定使用替代方法，征求专业知识的详细分析，我们认为，制定的政策问题，用于参与专家的机制和积极寻求证据的类型，继续边缘化的参与决策的吸毒者。
Over the past two decades, policymakers have been encouraged to develop evidence‐based policies in collaboration with experts. Drug policy is unique since it has an established inbuilt mechanism for soliciting expertise via the Advisory Council for the Misuse of Drugs (ACMD). Increasingly alternative mechanisms have been used. Based upon detailed analysis of two case studies of drug policymaking using alternative methods to solicit expertise, we argue that the framing of the policy problem, the mechanisms used to involve experts and the type of evidence actively sought, have continued to marginalise the involvement of the drug user in policymaking.